Global Digital Signature Market to Reach $2,934.6 Million by 2023     |    Global Outdoor Lighting Market to Witness 8.4% CAGR during 2017 - 2023     |    Oral Mucositis Therapeutics Pipeline to Receive More Drug Designations from the USFDA in the Coming Years

Toll Free (US/Canada): 1-888-778-7886

INT'L: 1-347-960-6455

enquiry@psmarketresearch.com

IgA Nephropathy Pipeline Analysis

P&S Market Research-IgA Nephropathy Pipeline Analysis report

IgA Nephropathy Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments

Published: April 2017
Report Code: LS10912
Available Format: pdf
Pages: 81

Pipeline Overview

Immunoglobulin A Nephropathy, also known as IgA nephropathy (IgAN) or Berger’s disease, is a kidney disorder that arises when IgA builds up in the kidneys, resulting in inflammation which causes damage to kidney tissues. IgA is an immunoglobulin A antibody produced by immune system for body protection from foreign substances such as viruses or bacteria. Production of IgA deposits damages the glomeruli and this results in blood and protein in urine. This progresses over time and eventually results in end stage renal disease (ESRD).

IgA nephropathy is a silent disease in its early stages with no symptoms. But the most common symptoms that are usually observed are proteinuria, leakage of protein in urine and hematuria, leakage of blood in urine. These symptoms can be observed by naked eyes as the urine color changes in both the conditions. The other signs and symptoms include high blood pressure, dry skin, feeling tired, nausea, little urination, weight loss, appetite loss and sleeping problems.

IgA nephropathy does not have a specific treatment, since when the kidneys get damaged they cannot be repaired. So the only treatment available is to prevent or delay ESRD. The process of kidney damage can be slowed down by the use of fish oil supplements, immunosuppressive drugs, corticosteroids angiotensin receptor blockers (ARBs) and angiotensin-converting-enzyme (ACE) inhibitors.

Pipeline Analysis

As of March 2017, the IgA nephropathy pipeline comprises of approximately 12 drug candidates, of which one drug candidate is in Phase III stage, five drug candidates are in Phase II stage and three drug candidates are in Pre-Clinical stage. Also, there are two inactive drug candidates and one discontinued drug candidate.

 

NUMBER OF IGA NEPHROPATHY DRUG CANDIDATES UNDER DEVELOPMENT (2017)

Pharma companies such as Mallinckrodt plc, Merck KGaA, Pharmalink AB, Anthera Pharmaceuticals, Inc., Rigel Pharmaceuticals, Inc., Omeros Corporation, Visterra, Inc., IGAN Biosciences, Inc. and Shire plc are actively involved in the development of IgA nephropathy pipeline. Seractide acetate is being developed by Mallinckrodt plc and is in Phase III clinical stage for the treatment of IgA nephropathy. It is a peptide administered by subcutaneous route and reduces remission of proteinuria.

Pharmalink AB is using TARGIT drug delivery technology platform for the development of Budesonide for IgA nephropathy. The TARGIT technology is based on the application of a combination of enteric polymers into injection-moulded starch capsules, for the targeted delivery of drugs to specific regions of the large intestine. The TARGIT capsule can accommodate relatively large doses of drug and can be filled with a wide range of formulations such as powders, granules, tablets, mini-tablets, coated pellets or semisolids.

Competitive Landscape

Several companies are involved in the development of IgA nephropathy pipeline, with their products in different phases. Mallinckrodt plc has its drug candidate in Phase III stage of development. Merck KGaA, Anthera Pharmaceuticals, Inc., Pharmalink AB, Rigel Pharmaceuticals, Inc. and Omeros Corporation, each have their drug candidate in Phase II stage of development. Shire plc has one drug candidate in Pre-Clinical stage of development.

Some of the key players developing drugs for IgA nephropathy include Mallinckrodt plc, Merck KGaA, Anthera Pharmaceuticals, Inc., Pharmalink AB, Rigel Pharmaceuticals, Inc., Omeros Corporation, IGAN Biosciences, Inc., Shire plc and Visterra, Inc.

Scope for Customization

P&S Market Research offers customization as per specific business requirements of clients. Illustrative customization within the scope of this report includes:

  • Market Forecast – Market analysis and forecast for the drug candidates in the last stage of development
  • Company Profiles – Wider company coverage in terms of detailed analysis or additional company profiles

Place An Order

Single User License

Single User License authorizes access of the publication to single user, i.e. the buyer of the report.

1850
Group License

Group License authorizes access of the publication upto 5 users.

2500
Site License

Site License authorizes access of the publication to all the employees of the organization at a single geographic location.

3500
Enterprise License

Enterprise License provides right to distribute copies of the publication across the organization and its subsidiaries.

5000
down-arrow

Pre-Purchase Enquiry

Contact Us

  • U.S. Center : 347 5th Ave. #1402- 210 New York City, NY 10016 United States
  • Asian Center : B-28, Sector 1, Noida, U.P. - 201301 India.

Secure Online Payments

  • Payment